Research about the serum calcineurin activity and the perhypertension left ventricular hypertrophy

Objective To investigate the role of the serum calcineurin(CaN)in perhypertension left ventricular hypertrophy.Methods From February 2011 to January 2014,282 healthy crowd were selected from The Jiangxi province People's Hospictal.Based on the blood pressure,all of them were divided into three groups:the normal blood pressure group(n=78),the perhypertension group(n=122) and the hypertension group(n=82).Based on the left ventricular mass index(LVMI)and the relative ventricular wall thickness(RWT),the perhypertension group were divided into two groups:the normal model subgroup(n=101) and the left ventricular hypertrophy subgroup(n=21).LVMI,RWT were determined by echocardiography;serum calcineurin levels were measured by the Enzyme-linked immunosorbent assay method;serum calcineurin enzymatic activities were measured by the colorimetric and serum Endothelin-1(ET-1)levels were measured by the radioimmunoassay method.The role of the serum CaN,ET-1 in perhypertension left ventricular hypertrophy was analyzed.Results ⑴In the normal blood pressure group,perhypertension group,hypertension group the incidence of the left ventricular hypertrophy were 7.82%,17.21%,22.35% respectively;the LVMI,RWT,serum CaN activity and serum ET-1 levels increased successively.There were significant differences(P0.05).The differences between the normal blood pressure group and the perhypertension group(P0.05)were more significant than the differences between the perhypertension group and the hypertension group(P0.01).⑵In the perhypertension group,the serum CaN activity、serum ET-1 levels in the Left ventricular hypertrophy subgroup were higher than the normal model subgroup(P0.05).Conclusion The incidence and serum CaN activity of the left ventricular hypertrophy in the perhypertension group were higher than that of the normal blood pressure group.The CaN activated advanced the occurrence and development of the left ventricular hypertrophy in the perhypertension.